NVE's spintronic sensors are locked into products that cannot requalify a second source. Once one is designed into a pacemaker or defense module, swapping it means redoing the whole safety qualification, and couplers carry 40-plus-week lead times once a design is locked. Revenue grew 81% year over year last quarter on $31M trailing, with 79% gross and 66% operating margins, net cash and a 0.84 PEG. The risk: at $486M and 14.9x EV/sales, growth must repeat against a brutal comparison next year. … Show more

NVE Corporation is a little-known, profitable small cap with major robotics upside because its spintronic sensors sit in humanoid robot hands, the biggest bottleneck in building capable humanoids. Revenue rose 81% to $11.03M and EPS to $1.32 from $0.74, before the robotics segment behind the thesis even showed up. NVE fabs its own wafers, earns ~79% gross margins with almost no debt, has been in Abbott pacemakers for 20+ years, and just doubled its factory with capex about to roll off. x.com 

NVE is a company worth liking but not owning now through 2027, because a historic bear market next year looks likely to drag everything down, regardless of the company's own scaling timeline. x.com  x.com  x.com 

NVE looks cheaper on annualized run-rate earnings than two weeks ago despite a 50% jump, because earnings grew so fast. Revenue rose 81% to $11.03M and EPS to $1.32 from $0.74, with 81.3% gross and 66% operating margins, driven by new products, a strong semiconductor market and precision automation and robotics. The defense ramp the thesis rests on has not yet appeared in the numbers. x.com 

Everspin's 38.6% surge to $18.28 after its Q1 beat has likely pulled forward much of the near-term upside: at about $425M, or 7x trailing sales, it already prices in much of 2026-2027 growth. Product sales grew 28% to $14.1M and a $40M defense contract bridges about $16M a year, but reaching $25-$30 needs quarterly revenue above $20M, hinging on July 2026 STT-MRAM qualification and a Microchip ramp with recurring orders not due until 2H 2027. Litigation costs weigh on GAAP income. x.com 

Everspin's execution does not match its monopoly: revenue growth has been inconsistent and margins all over the place, so results look worse than its positioning warrants. It is the world's only at-scale maker of Toggle MRAM, radiation-immune memory the US military uses in missiles, submarines and aerospace. Its new $40M Department of War contract requires it to hand over its process technology if it ever stops making MRAM, and a Microchip partnership adds domestic production in Oregon. x.com 

Everspin's MRAM is becoming indispensable for persistent, low-power, high-reliability computing at the edge, in vehicles and in defense, setting up a SanDisk-like breakout on a smaller scale if adoption accelerates. A move to $100 would not be shocking. This is high-conviction speculation: competition from embedded MRAM at scale, density and cost challenges, and a valuation already pricing in optimism make execution risk real, and analyst targets of about $12-18.50 lag the price. x.com  x.com 

Everspin Technologies is a high-risk MRAM pure play that could multiply if MRAM scales. Microchip's onshore MRAM foundry deal secures a second source, and expanded production feeds directly into revenue, with defense, space and AI-edge memory demand as beneficiaries. The real test is 2027-2029, when mass production, customer growth and revenue must show up; today expectations exceed results. Risks include a small, volatile company, customer concentration, an early market and production delays. … Show more

Everspin's MRAM rally makes little sense, as the market is not that large and there is no MRAM monopoly. Absent an unknown breakthrough using MTJs for AI, there is no reason for the bid, and the space angle, raised by @ryandonovan23, fails because data centers will never be in space. x.com  x.com  x.com 

Everspin is the only US-domiciled, US-manufactured MRAM maker, and its non-volatile, fast, radiation-hardened memory works where flash and DRAM cannot, making it a Pentagon supplier with no alternative. Its 10-year Microchip deal for a copy-exact line in Oregon doubles domestic capacity from H2 2027. Its UNISYST NOR flash replacement targets 5-10% of a $3 billion market, with production in 2027. It had 238 design wins in 2025, up 34%, with 52.7% gross margins and no debt. x.com  x.com  x.com  x.com  … Show more